Description

Molecular Partners AG is a clinical-stage biopharmaceutical company that specializes in the discovery, development, and commercialization of novel therapeutic proteins, leveraging its proprietary DARPin® technology. Its pipeline features several promising candidates: Abicipar, a DARPin-based therapy, is currently undergoing Phase III clinical trials for the management of both neovascular wet age-related macular degeneration (AMD) and diabetic macular edema. MP0420 is a multi-specific DARPin candidate being developed to address the SARS-CoV-2 virus. In the field of oncology, the company is advancing: MP0310, an immuno-oncology agent in Phase Ia trials. MP0317, a tumor-localized immune agonist in Phase I, designed to activate immune cells directly within tumor microenvironments. MP0274, also in Phase I, targeting HER2-positive cancers. Additional programs include MP0423 for COVID-19 treatment, MP0533 as a CD3 T cell candidate for acute myeloid leukemia, and MP0250, engineered to bind to vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and human serum albumin (HSA) to extend its half-life. The company has established significant strategic alliances, notably with Novartis AG for the co-development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies. Other key collaborators include Amgen SA and Allergan, Inc., alongside a discovery partnership with AbbVie Inc. focused on ophthalmology, in addition to various other third-party collaborations. Molecular Partners AG was established in 2004 and has its headquarters in Schlieren, Switzerland.